From Tom Sullivan’s Policy and Medicine blog, July 16, 2010:

As drug companies “prepare for new draconian provisions for reporting on financial relationships with prednisone vs hydrocodone academia,” a recent article in Nature Biotechnology investigated whether such efforts to “increase transparency will prove burdensome to researchers and the industry.”

The inquiry stems from “the latest fallout from Senator Charles Grassley’s (R-IA) campaign for increased transparency between physician researchers and industry.” This campaign has included numerous letters and investigations involving doctors, organizations and associations, agencies (e.g. NIH), medical journals, and drug and device companies.

Read more on their website, then come back here to comment.generic viagra soft tabs